C-Y9UACambridge Epigenetix
6-base genome, multiomics, epigenetic sequencing
research tools
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-Y9UA
C-Y9UAC-Y9UA6-base genome, multiomics, epigenetic sequencing
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Cambridge Epigenetix 6-base genome, multiomics, epigenetic sequencing
biomodal creates technologies that bring changing biology into focus by integrating multiple modes of biology from a single sample in a single experiment. Its duet multiomics solution evoC distinguishes 5-methylcytosine and 5-hydroxymethylcytosine alongside the four canonical DNA bases from low-input DNA samples. The site highlights applications in cancer research, neurodegenerative disease, ageing, precision medicine, liquid biopsy, and non-invasive prenatal testing.
The published score reflects a curated read of public evidence across 16 dimensions. Each dimension below shows the rationale we used. Disagree with a reading? Tell us where we are wrong →
Higher up = higher Eternal Search score. Further right = closer to achieving real longevity outcomes (early mechanism → translational → near-term readout). Bubble size = capital deployed. Watch for MISMATCHES: big bubbles on the left are well-capitalized but far from goals; small bubbles on the right are doing more with less.
Cambridge Epigenetix — Far from goals · Lower middle. Derived deterministically from 3 extracted project(s). Most-advanced status: undisclosed. Band: far. Aging-relevance not LLM-reviewed in this pass.
Source: Deterministic